Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'Bepirovirsen Liver Biopsy study'. The following are the other relevant details related to the tri... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCL... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyro... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarker... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'Evaluating the efficacy and safety of Platelet Rich Plasma for patients with Peyronie’s disease: ... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'SURFactant Administration by SUPraglottic Airway (the SURFSUP Trial)'. The following are the othe... Read More
Singapore, Sept. 22 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with... Read More